CryoLife SEC Probe Compounds Firm’s Regulatory Woes; FDA Issues Notice
This article was originally published in The Gray Sheet
Executive Summary
The Securities and Exchange Commission is seeking information from CryoLife on corporate accounting from October 2001 to the present related to a company recall of tissue products, as well as stock trading activity